Live feed08:00:00·2028dPRReleasevia QuantisnowCatalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with InhibitorsByQuantisnow·Wall Street's wire, on your screen.CBIO· Crescent Biopharma Inc.Health CareOriginal source
